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A B S T R A C T   
Introduction: Paternal low-protein diet can alter sperm methylation status, fetal growth and program offspring ill- 
health, however its impact on the placenta remains poorly defined. Here we examine the influence paternal low- 
protein diet has on fetal and placental development and the additional impact of supplementary methyl-donors 
on fetoplacental physiology. 
Methods: Male C57BL/6J mice were fed a control normal protein diet (NPD; 18% protein), a low-protein diet 
(LPD; 9% protein) or LPD with methyl-donor supplementation (MD-LPD; choline chloride, betaine, methionine, 
folic acid, vitamin B12) for a minimum of 8 weeks. Males were mated with 8–11 week old female C57BL/6J mice 
and fetal and placental tissue collected on embryonic day 17.5. 
Results: Paternal LPD was associated with increased fetal weights compared to NPD and MD-LPD with 22% fe-
tuses being above the 90th centile for fetal weight. However, LPD and MD-LPD placental weights were reduced 
when compared to NPD. Placentas from LPD fathers demonstrated a reduced junctional zone area and reduced 
free-fatty acid content. MD-LPD placentas did not mirror these finding, demonstrating an increased chorion area, 
a reduction in junctional-specific glycogen staining and reduced placental Dnmt3bexpression, none of which were 
apparent in either NPD or LPD placentas. 
Discussion: A sub-optimal paternal diet can influence fetal growth and placental development, and dietary 
methyl-donor supplementation alters placental morphology and gene expression differentially to that observed 
with LPD alone. Understanding how paternal diet and micro-nutrient supplementation influence placental 
development is crucial for determining connections between paternal well-being and future offspring health.   
1. Introduction 
Placental dysfunction can cause extremes in fetal growth, such as the 
development of small for gestational age (SGA) babies (defined as a fetal 
weight under the 10th percentile for the population at that gestational 
age) or fetal overgrowth (a fetal weight over the 90th percentile, termed 
large for gestational age (LGA)) [1,2]. These abnormalities in fetal 
growth are highly prevalent worldwide, and have been linked to an 
increased risk of stillbirth and childhood morbidities [3–5]. There is also 
evidence that inappropriate growth in utero can impact childhood 
development and offspring health in adulthood [6]. David Barker and 
colleagues’ extensive studies of epidemiological data developed the 
‘fetal programming’ hypothesis, and first demonstrated associations 
between maternal nutrition, impaired fetal growth and the risk of 
developing cardiovascular or metabolic disorders in later life [7–9]. This 
hypothesis suggests exposure to sub-optimal environments during 
crucial developmental time-points can alter fetal growth trajectories, 
predisposing the offspring to increased risk of poor health in later life 
[6]. 
A range of human and animal model studies have explored the role of 
maternal diet during gestation on placental and fetal development [10, 
11]. More recently, studies have identified the pre-conception period as 
a critically sensitive time during which adverse environmental condi-
tions can affect fetal development and offspring health [12]. In mice, a 
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maternal low-protein diet fed exclusively during oocyte maturation 
altered offspring behavioural phenotype and increased their suscepti-
bility to cardiovascular disease [13,14]. Similar findings have been re-
ported in sheep, where maternal peri-conceptional caloric restriction 
resulted in cardiovascular abnormalities in the lambs, including 
increased heart rate and blood pressure [15]. Maternal 
peri-conceptional folate, vitamin B12 and methionine restrictions in 
sheep have also been shown to reduce fetal liver DNA methylation levels 
and program increased adiposity and cardiovascular dysfunction in the 
offspring [16]. As our understanding of the sensitivity of the pre- and 
peri-conception period expands, a new focus on the role the father’s diet 
has for embryo development, implantation and fetal growth is emerging. 
We have previously shown that a paternal sub-optimal low-protein 
diet (LPD) in mice resulted in increased adiposity, vascular dysfunction 
and impaired glucose tolerance in his offspring [17]. We also observed 
significant changes in expression of genes involved in metabolism, 
transcription and signalling cascades in the blastocyst [18]. In addition, 
we found that paternal LPD programmed fetal overgrowth and altered 
expression of placental transport, DNA methylation and imprinted 
genes, predisposing these offspring to cardiovascular and metabolic 
disorders in adulthood [17,18]. Paternal LPD has also been associated 
with a reduction in testicular DNA methyltransferase gene expression 
and changes in expression of genes involved in the 1-carbon metabolism 
pathway [19,20], alongside a global hypomethylation of their sperm 
[19]. A separate study examining reduced paternal folate intake in mice, 
found this dietary regime resulted in fetal craniofacial abnormalities and 
limb underdevelopment, which were associated with sperm DNA 
methylation status [21]. These studies not only show that paternal diet 
can influence embryo development but that his diet can influence the 
epigenetic status of the fetus, thus influencing developmental pro-
gramming of the offspring [22,23]. However, there is a paucity of in-
formation regarding the impact paternal health has on the placenta. This 
study aimed to determine how paternal LPD in mice influences the 
placenta, with further investigations examining whether methyl-donor 
dietary interventions ameliorate any observed impairments to fetal or 
placental development, due to the intimate involvement of the 1-carbon 
metabolism in regulating epigenetic signatures. 
2. Materials and methods 
2.1. Animals and diet regimen 
All animal procedures were approved by the Home Office according 
to the Animals (Scientific Procedures) Act 1986 (Project License 30/ 
3253) and local ethical approval at Aston University. All C57BL/6J mice 
(Charles River, UK) were housed in controlled 12/12-h light/dark con-
ditions with a constant temperature (21 ◦C ± 3 ◦C) and ad libitum access 
to water. Virgin 8-week old males were fed either control normal protein 
diet (NPD; 18% casein; n = 7), isocaloric low protein diet (LPD; 9% 
casein; n = 7), or isocaloric LPD supplemented with methyl-donors [an 
addition of 5 g/kg diet choline chloride, 15 g/kg diet betaine, 7.5 g/kg 
diet methionine, 15 mg/kg diet folic acid, 1.5 mg/kg diet vitamin B12 to 
LPD (MD-LPD; n = 6)] for a minimum of 8 weeks to ensure all stages of 
spermatogenesis were exposed to the diets, as previously described [20]. 
Dietary components are outlined in Supplementary Table 1. 
Virgin female C57BL/6J mice were mated at 9-weeks old (±7 days) 
with stud males from one of the three diet groups (NPD; n = 7, LPD; n =
7, MD-LPD; n = 6). Successful mating was confirmed by the presence of a 
copulation plug, denoted as embryonic day (E)0.5. The dams were fed 
and maintained on standard rodent chow (rat/mouse No.1 maintenance 
diet, Special Diet Services), for the remainder of gestation. At E17.5 
dams were euthanized via cervical dislocation and fetal and placental 
weights recorded. Placentas were collected from the middle two fetuses 
within each uterine horn (where possible); one snap-frozen and stored at 
− 80 ◦C for molecular investigations and the other fixed in 10% neutral 
buffered formalin (Sigma; UK) at room temperature overnight, stored in 
70% ethanol and processed for histology on a Thermo-Scientific Excel-
sior tissue processor. 
2.2. Analysis of placental morphology and glycogen 
Formalin fixed-paraffin embedded placental tissue was sectioned at 
5 μm through the mid-line using a Leitz 1512 rotary microtome (Leica). 
Placental sections were stained with haematoxylin and eosin to assess 
gross morphological structure and layer proportions. Placental glycogen 
was stained using a periodic acid Schiff (PAS) stain. Briefly, sections 
were dewaxed and rehydrated before incubation with 0.5% periodic 
acid (Sigma, UK) for 90 min. Sections were then washed and incubated 
in Schiff’s reagent (Sigma, UK) for 15 min, before dehydrating and 
mounting in DPX. The percentage of positive magenta staining was 
measured by a blinded operator using Image J software. 
Total placental glycogen content was determined using the protocols 
of Lo et al. (1970) and Rampon et al. (2008) with some modifications 
[24,25]. Briefly, 10 mg of placental tissue was homogenised in 30% KOH 
saturated with Na2SO4 (Sigma, UK) and incubated at 100 ◦C for 30 min, 
followed by cooling on ice. Glycogen was precipitated in 100% ethanol 
and separated by centrifugation at 1,000×g for 30 min. Glycogen stan-
dards were prepared using Rabbit Liver Glycogen (G8876; Sigma, UK), 
with concentrations ranging from 400 μg/ml to 12.5 μg/ml. Samples and 
standards were combined with 5% phenol with H2SO4 (Sigma, UK) to 
initiate a colorimetric change. Absorbance was read at 490 nm on 
Benchmark Bio-Rad microplate reader. 
2.3. Free fatty acid profile 
Total placental free fatty acids (FFA) were quantified using the 
commercially available free fatty acid assay kit (ab65341, Abcam, UK). 
The extraction, preparation and colorimetric measurements of samples 
and standards was performed according to manufacturer’s instructions. 
Briefly, 10 mg of placental tissue was homogenised in 1% TritonX-100 in 
chloroform (Sigma, UK), using Qiagen TissueLyserII (25 Hz, 2 × 30 s), 
centrifuged at 17,000×g at 4 ◦C for 10 min and the organic phase dried 
and re-constituted in assay buffer. Sample and standard absorbance 
were read at 570 nm on Benchmark Bio-Rad microplate reader. Con-
centrations were interpolated from the standard curve after blank sub-
traction and corrected for dilution, volume of sample and placental 
weight. 
2.4. Cholesterol content assay 
Placental lysate was obtained from 10 mg placental tissue in chlo-
roform as outlined above. The cholesterol content of the dried lipids was 
determined using the Amplex-Red Cholesterol Assay Kit (A12216, 
Invitrogen), following manufacturer’s instructions. Absorbance was 
read at 540 nm on Benchmark Bio-Rad microplate reader. Concentra-
tions were interpolated from the standard curve after blank subtraction 
and corrected for dilution and weight of placental tissue. 
2.5. Placental RNA extraction and gene expression 
Placental RNA was extracted from 20 to 25 mg of frozen placental 
tissue using the RNeasy mini kit (Qiagen, UK), following tissue disrup-
tion in Qiazol (Qiagen, UK) using the Qiagen TissueLyserII (25 Hz, 4 ×
30 s), according to manufacturer’s instructions. RNA concentration was 
quantified by Nanodrop and cDNA templates produced using Precision 
nanoScript2 RT kit (PrimerDesign, UK) according to the manufacturer’s 
instructions, with RNA input standardised for 1 μg. Real-time quanti-
tative PCR was used to determine expression of key epigenetic and 
imprinted genes previously found to be dysregulated in the sperm and/ 
or placenta in response to LPD [18,19], using 5 ng cDNA and 175 nM 
forward and reverse primers (Eurofins Genomics, Germany) with 1x 
Precision SYBRgreen Mastermix (PrimerDesign, UK) per reaction. All 
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RT-qPCR was performed using an Applied Biosystems 7500 system. 
Gene expression was analysed using the delta-delta Ct method relative to 
NPD expression, the GeNorm method was used to normalise gene 
expression, as previously described [26], to two reference genes (Tbp 
and Tuba). Briefly the geometric mean of both reference genes was 
calculated for all samples, and for the total number of samples used, to 
construct a normalisation factor which was then used to normalise each 
samples’ gene expression. Details of all primers can be found in Sup-
plementary Table 2. 
2.6. Placental DNA extraction and methylation quantification 
Total placental DNA was extracted from 20 to 25 mg of placental 
tissue using the DNeasy Blood & Tissue Kit (Qiagen, UK), following 
tissue disruption in Buffer ATL (Qiagen, UK) using the Qiagen Tissue-
LyserII (25 Hz, 4 × 30 s), according to manufacturer’s instructions. DNA 
concentration was quantified by Nanodrop and samples diluted to 50 
ng/μl. Global DNA methylation was quantified using the Methylated 
DNA Quantification Kit (ab117128, Abcam, UK) following manufac-
turer’s instructions with plates read at 450 nm, 2 min from reaction end, 
on a Benchmark Bio-Rad microplate reader. The relative levels of 5- 
methylcytosine were expressed as a percentage compared to the in-kit 
methylated polynucleotide positive control. 
2.7. Statistical analysis 
Fetal and placental data were analysed using generalised linear 
mixed model analysis, factoring for dam, littersize and uterine position, 
using SPSS [27]. Percentiles for NPD data were calculated using the 
formula (Z-critical × SD) + mean; where Z-critical value was − 1.2816 
(10th centile) and 1.2816 (90th centile) and statistical significance was 
determined using Chi2-test. Analysis and graphical interpretations of all 
other data were performed using GraphPad Prism (v7.0). Where 
appropriate, normality was assessed using Shaprio-Wilk and 
Kolmogorov-Smirnov tests, in the case data was normally distributed, 
one-way ANOVA with Tukey’s post-hoc test was performed, and where 
data were not normally distributed, Kruskall-Wallis test with Dunns 
multiple comparison test was performed. Significance was determined 
as p < 0.05. 
3. Results 
3.1. Maternal characteristics 
There was no significant difference in dam weight immediately 
following successful mating (Fig. 1A), at E17.5 (Fig. 1B) or after sub-
traction of total conceptus mass (non-gravid weight gain) (Fig. 1C). 
Additionally, no significant differences were observed in the maternal 
weight gain normalised for the number of fetuses (Fig. 1D). 
3.2. Paternal diets impact on late gestation fetal and placental weights 
We have previously published that neither the paternal LPD, nor the 
supplemented MD-LPD, influence male reproductive success, as E17.5 
litter size was not significantly altered when compared to NPD [20]. 
Fetuses sired from LPD fed fathers had a significantly increased weight 
at E17.5 compared to NPD (p = 0.0113) and MD-LPD (p = 0.0018) fe-
tuses. (Fig. 2A). Fetal weight distributions revealed LPD fathers pro-
duced a higher proportion of ‘overgrown’ fetuses; 22% fall above the 
90th centile for NPD fetal weights, however this did not reach signifi-
cance when compared to NPD (Fig. 2B). In contrast, MD-LPD fetuses 
demonstrated a significantly reduced proportion of fetuses above this 
centile (1.9%) compared to NPD (p = 0.0294) and LPD (p = 0.0013) 
(Fig. 2B). Placental weights were found to be significantly reduced in 
both LPD (p = 0.0158) and MD-LPD (p = 0.0159) groups when 
compared to NPD placentas (Fig. 2C). The distributions of placental 
weights did not reflect the trends observed in the fetal weight distri-
butions, and demonstrated a significant reduction in the proportion of 
placental weights above the 90th centile, with all placental weights in 
LPD (p = 0.0047) and MD-LPD (p = 0.0072) groups falling below this 
threshold (Fig. 2D). The fetal:placental ratio was examined as an indi-
cation of placental efficiency. We found that this ratio was significantly 
increased in LPD compared to NPD (p = 0.0005) and MD-LPD (p =
0.0386) groups (Fig. 2E). However, there was no significant difference 
Fig. 1. Maternal pregnancy associated weight gain. Maternal body weight at E0.5 (A), E17.5 (B), gestational weight gain independent of total conceptus mass (C) and 
mean weight gain per fetus (D). Data points represent individual dam, with mean ± SEM; statistical significance was determined using one-way ANOVA with Tukey 
post-hoc test, comparing the three diet groups; n = 6–7. 
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in fetal:placental ratio between NPD and MD-LPD fetuses (Fig. 2E). 
There was no differences between diet groups in yolk sac weight, or 
heart:body weight ratio of the fetuses (Fig. 2F and G). Fetuses from 
MD-LPD fed fathers demonstrated significantly increased liver:body 
weight compared to NPD fetuses (p = 0.0412) (Fig. 2H). 
3.3. Paternal diets impact on placental morphology 
Representative images of H&E stained placental sections, high-
lighting the junctional, labyrinth and chorion zones, are shown in 
Fig. 3A. Overall, MD-LPD placentas had a significantly increased whole 
placental cross-section area compared to LPD (p = 0.0082), but no sig-
nificant alterations were observed in LPD or MD-LPD when compared to 
NPD (Fig. 3B). LPD placentas did demonstrate a significant reduction in 
junctional area compared to NPD (p = 0.0383) and MD-LPD (p =
0.0009) placentas (Fig. 3B). MD-LPD placentas also demonstrated an 
expanded chorion area compared to both NPD (p = 0.0419) and LPD (p 
= 0.0284). The labyrinth area was the only zone area not to be impacted 
by any of the paternal diets (Fig. 3B). Upon examination of the layer 
proportions, we found placentas from LPD fathers had significantly 
reduced junctional zone percentage, and thus a proportionally increased 
labyrinth zone (p = 0.0275 vs NPD and p = 0.0265 vs MD—LPD) 
(Fig. 3C). 
3.4. Placental glycogen content 
Glycogen content of the placenta was analysed with a biochemical 
assay and PAS staining. The placental glycogen content of whole 
placental tissue was not significantly different between any of the diet 
groups (Fig. 4A). The PAS stained placenta revealed the majority of 
glycogen positive staining was localised to the junctional zone, and this 
was significantly reduced in MD-LPD placentas when compared to NPD 
Fig. 2. Paternal diet impacted fetal and placental 
parameters at E17.5. Fetal weights (A) and their dis-
tributions (B), placental weights (C) and their distri-
butions (D), the fetal:placental weight ratio (E) and 
yolk sac (F). Fetal organs were dissected to allow 
calculations of the heart:fetal weight ratio (G) and 
liver:fetal weight ratio (H). Data presented as dot plot 
where each data point is average of entire litter, with 
line representation of mean ± SEM (N = 6–7 litters; n 
= 53–59 fetuses), statistical significance determined 
using a generalised linear mixed model analysis, *p <
0.05, **p < 0.01, ***p < 0.001; or as violin plot of all 
fetuses (n = 53–59) with the 10th and 90th centiles 
denoted by grey areas, significant differences in 90th 
centile proportions and 10th centile proportions 
calculated using Chi2 test, *p < 0.05, **p < 0.01 vs 
NPD and ††p < 0.01 vs LPD.   
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(p = 0.0022) and LPD (p = 0.0002) (Fig. 4B and C). 
3.5. Placental free-fatty acid and cholesterol content 
Placental free-fatty acid (FFA) concentrations were significantly 
reduced in whole placental extracts from LPD placenta compared to NPD 
(p = 0.0115) and MD-LPD (p = 0.0332) (Fig. 5A). The ratio of placental 
FFA and fetal weight was significantly reduced in the LPD group 
compared to NPD (p = 0.0041), with no significant differences observed 
in the MD-LPD ratio or in the FFA:placental weight ratio for any dietary 
groups (Fig. 5B and C). Paternal diet did not significantly alter placental 
cholesterol content per mg of placenta tissue (Fig. 5D), however there 
was a trend towards a reduced concentration in MD-LPD placentas (p =
0.0573). The ratios of placental cholesterol:fetal weight and cholesterol: 
placental weight were not significantly different between diet groups 
(Fig. 5E and F). 
3.6. Placental expression of epigenetic regulatory and imprinted genes 
Of the investigated genes involved in epigenetic processes (Fig. 6A), 
MD-LPD placentas demonstrated a significantly reduced expression of 
Dnmt3b compared to NPD (p = 0.0212) and LPD (p = 0.0184) (Fig. 6A). 
However, there was no significant difference in the global proportion of 
methylated placental DNA (Fig. 6B). None of the three paternally 
expressed genes investigated demonstrated any significant changes in 
placental expression between the diet groups (Fig. 6C). 
Fig. 3. Paternal diet altered placental area. Repre-
sentative images of H&E stained placenta with junc-
tional (JZ) and labyrinth (LZ) zones and chorionic 
plate (CP) annotated (A). Measured placental area of 
whole placenta and respective zones (B) and the 
representative proportions of the three distinct zones 
(C). Each data point represents a single placenta, n =
4–6 litters (1–2 placenta assessed from each litter), 
data presented with mean ± SEM. Statistical signifi-
cance was determined using one-way ANOVA for 
each zone with Tukey post-hoc test comparing the 
three diet groups; *p < 0.05, **p < 0.01, ***p <
0.001.   
Fig. 4. Assessment of paternal diet’s impact on 
placental glycogen. Whole placental glycogen content 
(A) and positive PAS staining within placental zones, 
expressed as a proportion of total zone area (B). 
Representative images of PAS stained placental sec-
tions for each diet group, with a magnified view of 
positive junctional zone staining (C). Data presented 
as mean ± SEM, with each data point representing a 
single placenta; n = 4–6 litters (1–2 placenta assessed 
from each litter). Statistical significance was deter-
mined using one-way ANOVA with Tukey post-hoc 
test, comparing the three diet groups; **p < 0.01, 
***p < 0.001.   
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4. Discussion 
There is increasing evidence that the father plays a prominent role in 
fetal programming, yet the mechanisms through which any sub-optimal 
paternal environment has on the development of his offspring is still 
relatively ill-defined. This study has provided evidence that paternal 
LPD increased late gestation fetal weight, yet was associated with a 
reduction in placental weight compared to NPD. Placentas from LPD 
fathers had a reduced junctional zone area and reduced free-fatty acid 
content, with no alteration in expression of key epigenetic and imprinted 
genes. This study also provided evidence that whilst supplemental di-
etary methyl-donors negate the observed LPD-directed fetal overgrowth, 
the placental phenotype did not mirror that of NPD or LPD groups. MD- 
LPD placentas exhibited a reduced weight, similar to LPD, yet did not 
demonstrate the LPD-associated proportional layer differences. MD-LPD 
placentas demonstrated unique findings; such as a reduced junctional 
specific glycogen content and reduced expression of Dnmt3b, the DNA 
methyltransferases gene involved in de novo methylation and increased 
Fig. 5. The impact of paternal diet on placental free fatty acid and cholesterol metabolism. Biochemical assay of E17.5 placental free fatty acid (FFA) (A), with the 
FFA content expressed as a proportion of fetal weight (B) and placental weight (C). Placental cholesterol content (D), expressed as a proportion of fetal weight (E) and 
placental weight (F). Data presented as mean ± SEM, with each data point representing a single placenta, n = 6–7 placentas (1 placenta/litter). Statistical significance 
was determined using one-way ANOVA with Tukey post-hoc test, comparing the three diet groups; *p < 0.05, **p < 0.05. 
Fig. 6. The placental expression of genes involved in 
epigenetic regulation (A) and the quantification of 
total placental 5-methylcytosine DNA methylation 
(B). Placental expression of three key paternally 
imprinted genes (C). All gene expression data pre-
sented relative to NPD expression normalised to 
TbpandTubareference gene expression. n = 6–7 pla-
centas (1 placenta/litter), statistical significance 
determined using either one-way ANOVA with Tukey 
post-hoc test or Kruskall-Wallis with Dunns post-test, 
comparing the three diet groups for each gene; a = p 
< 0.05 vs NPD, b = p < 0.01 vs LPD.   
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chorion area. Thus, the supplementation of paternal LPD with methyl- 
donors did not prevent all LPD-directed changes to the placenta and 
exhibited a differentially altered structure. Yet, MD-LPD placentas sup-
ported fetal growth to a level similar to that of NPD placentas. 
In this study, paternal LPD significantly increased fetal weight, 
similar to previous observations by our group [18]. We also observed a 
shift in the distribution of LPD fetal weight, with 22% of fetuses 
exceeding the 90th centile for NPD weights. There is growing evidence 
in humans, that LGA offspring are at an increased risk of developing 
diabetes [28], obesity [29] and even some cancers [30]. Previous studies 
have found that a maternal low-protein diet in mice during the 
pre-conceptional period can increase fetal weight [27,31]. However, 
studies investigating the impact of paternal diet have had conflicting 
results. Paternal undernutrition (diet restricted to 70% of control intake) 
in mice has been found to reduce offspring weight, cause dyslipidaemia 
and alter adipose accumulation [32]. A similar finding was observed in 
mice with diet-induced paternal obesity, where both placental and fetal 
weights were reduced at term [33]. However, a separate paternal 
obesity mouse model found this dietary regime had no impact on fetal or 
placental weights [34], and another found that paternal diet-induced 
obesity resulted in heavier neonates which demonstrated impaired 
glucose tolerance and insulin resistance in later life [35]. Previous work 
investigating the physiology of males fed LPD and MD-LPD has 
demonstrated that there is no weight change in males fed LPD, however 
males fed MD-LPD exhibited increased weight gain and adiposity 
compared to NPD [20]. We have shown, in the current study, that the 
fetuses sired by these MD-LPD males had reduced weights compared to 
LPD and demonstrated a significantly reduced proportion of fetuses 
below the 90th centile. Interestingly, this data suggests that 
methyl-donor vitamin/mineral supplementation may prevent an 
LPD-associated overgrowth. Paternal folate deficiency has been shown 
to reduce fetal weight in rats [36], and has been associated with fetal 
and placental malformations in mice [21]. Conversely, supplementation 
of a restricted paternal diet with vitamins and antioxidants (including 
folate, vitamin C and vitamin E), in mice, was found to negate the 
offspring growth restriction observed with paternal undernourishment 
[32]. In humans, Pauwels et al. utilised detailed food diaries to calculate 
methyl-donor intake in men and determine associations between intake 
of methyl-donors (e.g. methionine, choline and betaine) and birth 
weight [37]. They found that different methyl-donors may correlate 
with changes in birth weight; with betaine and methionine demon-
strating a negative association and choline a positive [37]. From these 
studies, it can be inferred that paternal micro/macronutrient balance is 
an important factor that must be considered when assessing reproduc-
tive outcomes. However, the males fed MD-LPD were previously found 
to have an increased weight gain and increased serum saturated fatty 
acids [20], which could suggest these males have a different metabolic 
profile to LPD and NPD. Therefore, it is not possible to discriminate 
between the programming effects of the methyl donors alone from those 
that may occur in response to the increased adiposity in MD-LPD males. 
Obesity in males is associated with a myriad of fertility related issues, 
such as impaired sperm motility, count and morphology, and has been 
associated with alterations in early fetal development [34,38,39]. 
Consequently, it must be taken into consideration that the MD-LPD 
associated fetal and placental changes observed in this study may be 
related to a change in paternal metabolic environment rather than a 
simple addition of methyl donors to a sub-optimal diet. 
The placenta, being the organ dictating fetal weight, would be ex-
pected to follow the same growth distribution as its fetus. However, we 
did not find this to be true in this study. LPD and MD-LPD placentas had 
significantly reduced placental weights and LPD placental weight dis-
tributions did not follow the same pattern as the respective fetal weight 
distributions. Thus, in response to paternal LPD, the overgrown fetus is 
being supported by a placenta of reduced weight. This could suggest that 
a paternal LPD produces a more efficient placenta, reflected by the 
increased fetal:placental ratio. MD-LPD placentas, whilst demonstrating 
a significantly reduced weight, compared to NPD placentas, did not 
reflect the fetal:placental relationships of the LPD group. This could 
suggest that the absence of fetal overgrowth in this supplemented group 
was due to a change in the placental transport flux. However, fetal: 
placental ratios as a proxy for placental efficiency are only at best an 
estimation [40]. To fully answer how placental transport is impacted by 
paternal diet the expression and function of key transporters should be 
examined. Animal studies examining the influence of maternal 
under-nutrition on placental transport have revealed conflicting results. 
A low-protein diet in pregnant rats was found to reduce placental 
transport capacity, specifically involving a reduction in sodium-coupled 
amino acid transport, leading to growth restricted fetuses [41,42]. 
Further maternal under-nourishment studies in the rat found that the 
placental expression of glucose and amino acid transporters (SLC2A3, 
SLC38A2 and SLC38A3) was reduced, yet SLC38A4 was found to in-
crease in response to a restricted diet [43]. Alternatively, studies 
investigating maternal undernutrition in mice have hypothesised a 
compensatory transport response, in that a restricted diet increases 
placental expression of Slc2a1 and Slc38a2 and placental transport of 
neutral amino acids at term, however these studies still observed fetal 
growth restriction [44,45]. We have previously shown that our paternal 
low protein diet increased the expression of placental mRNA expression 
of glucose transporters (Slc2a1, Slc2a4), amino acid transporters 
(Slc38a2, Slc38a4) and the calcium transporters, Atp2b1 [18]. There is 
further evidence suggesting paternal high-fat diet can impact placental 
mRNA expression Slc6a19 in a sex-specific manner, with females more 
affected that than males [46]. This raises an important caveat of 
placental investigations, that the sex of the fetus, and thus the placenta, 
can impact its response to sub-optimal conditions. Sex of the placenta is 
a crucial regulator of its transport and function [47], and male offspring 
have been found to have significantly poorer outcomes in pregnancies 
complicated by growth restriction [48] It was unfortunately not possible 
in our current study to investigate the fetal sex impact on response to 
poor-paternal diet. 
The assessment of the placental phenotype conducted in this study 
revealed a proportional reduction of the junctional zone of LPD pla-
centas, compared to both NPD and MD-LPD. The full functions of the 
junctional zone are not completely understood; however, there is evi-
dence to suggest this zone acts as a site of energy reserves for the 
placenta and undertakes crucial endocrine functions; that are essential 
for fetal development as well as stimulating essential pregnancy-related 
adaptations to the maternal cardiovascular, immune and metabolic 
systems [49–51]. Whilst there are very few studies examining placental 
layer structure in relation to paternal diet, junctional zone abnormalities 
have been identified in placentas from undernourished mothers [44, 
52–54]. In a mouse model of sustained maternal protein restriction, the 
junctional zone area was found to be significantly reduced throughout 
gestation [54]. This study attributed the junctional size reduction to a 
loss of glycogen trophoblast (GlyT) cells [54]. In our current study the 
LPD-associated reduction in junctional zone proportion was not associ-
ated with a reduction in glycogen staining. Conversely, whilst MD-LPD 
placentas did not show any proportional junctional size differences 
compared to NPD, they exhibited a significant reduction in 
junctional-specific glycogen staining. The PAS staining used in the 
present study is commonly utilised to identify glycoproteins and has 
been used to highlight the location of GlyT [49]. These trophoblasts are 
proposed to act as energy reserves for the placenta, with the glycogen 
stores depleting as the fetal growth becomes exponential nearer term 
[49,55]. The decreased abundance of PAS positively stained cells in the 
MD-LPD placental junctional zone, suggests a loss of glycogen. However 
this would require assessment of the presence/absence of key receptors 
on glycogen cells and enzymes associated with glycogenolysis, such as 
glucose 6-phosphatase and glucagon, to affirm this speculation. 
Glycogen trophoblast cells have been found to have increased glucagon 
expression towards term, as it becomes necessary to utilise glycogen 
stores as glucose to support exponential fetal growth in late gestation 
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[49]. Aberrations in placental glycogen storage and the reduction of 
GlyT numbers have been linked to a reduced fetal growth in both animal 
models and humans [56,57]. Previous studies have observed a reduced 
E15.5 placental glycogen content when maternal choline is supple-
mented throughout gestation in mice [58]. However by the end of 
gestation this was no longer apparent, with a higher glycogen content 
found as choline supplementation increased. The dynamic changes of 
glycogen content across gestation highlight the imperative need to 
assess whether there is an impairment of glycogen accumulation in 
MD-LPD placentas prior to E17.5 that altered histological glycogen 
abundance noted in our study, however this would require further 
detailed analysis of earlier gestational time-points as well as investiga-
tion of key genes involved in glycogen storage in the placenta, such as 
glycogen synthase. Furthermore, there was no significant difference in 
total placental glycogen content in this study. This could be due to the 
specific junctional location of glycogen, and in examining a mix of 
junctional and labyrinth zones any proportional differences were 
removed and thus the global placental assay may not be revealing the 
finer details. A more detailed investigation of this placental zone is 
required to fully understand the paternal diets relationship with GlyT 
and glycogen storage in the placenta. 
MD-LPD placentas also demonstrated an increased whole placental 
area and junctional zone area compared LPD placentas, and the chori-
onic plate area was significantly greater than that of both NPD and LPD 
placentas. This suggests a disproportionate increase in layer composi-
tion in placentas from MD-LPD fathers, due to the labyrinth zone 
remaining similar to NPD. The chorionic plate plays a key role in the 
formation of the labyrinth layer [59]. The early chorionic ectoderm 
(pre-E9.0) has been found to be crucial in supporting labyrinth layer 
development with the abundance of trophoblast-stem cell progenitors 
[60], thus a change in chorion layer area could suggest that paternal 
methyl-donor supplementation has the potential to influence the lineage 
programming of the placenta. Under normal conditions the chorion area 
decreases as the labyrinth area increases, from approximately E12.5 [52, 
60]. It is unclear in this study why MD-LPD placentas demonstrate an 
expanded chorionic plate area yet no change in labyrinth area, to fully 
answer this an earlier time-point in placental development would need 
to be examined in future studies. The finding of increased total placental 
area but no change in proportions, alongside a reduction in placental 
weight suggest MD-LPD placentas had an altered shape. A more domed 
shape, with a possible reduction in placental circumference could ac-
count for these findings. Studies investigating SGA babies in humans 
have found evidence that a reduced placental diameter and smaller 
placental mass are associated with a reduced fetal weight [61]. This 
leads to an explanation for the observed fetal weight reduction in the 
MD-LPD group, however it cannot be purely size-related as these pla-
centas had similar weights to the LPD placentas that produced over-
grown fetuses. It is possible that there are more functional mechanisms 
at play within the placenta, potentially influencing placental transport, 
with paternal diet altering the synchronisation between placenta and 
fetus. Furthermore, the results reported in our study are not absolute 
volume measurements of placental areas, and thus cannot ascertain any 
firm conclusions regarding placental structure. A more robust analysis of 
the specific cell types and defined spaces (i.e. maternal blood space, fetal 
capillary areas etc.) would better define the influence of sub-optimal and 
supplemented paternal diets on placental structural. 
To further determine placental adaptations in relation to the LPD- 
associated increased fetal growth, we assessed placental metabolism, 
investigating the FFA and cholesterol content. We found a reduced 
placental FFA concentration in LPD placentas compared to NPD and MD- 
LPD. The placenta regulates FFA delivery to the fetus, thus a lower 
concentration of FFA present in E17.5 placentas suggests reduced de-
livery. However, as the LPD fetal weights were elevated above NPD 
weights, it could be possible that there has been an accelerated fetal 
growth prior to this time point or that the growth is not dependent on 
FFA availability. In models of maternal nutrition, the reduced levels of 
FFAs in the diet have been associated with neurological development 
and metabolic disorders in the offspring [62,63]. Yet, our assessment of 
placental FFA content does not factor into account the possibility of 
altered FFA transport rates or metabolism. Modelling of the placental 
fatty acid transfer across the placenta by Perazzolo et al. suggested that 
fatty acid metabolism is the rate-determining factor for maternal FFA 
uptake, not membrane transport [64]. However, the majority of studies 
observing dysregulated placental transport of FFAs has been conducted 
in models of maternal over-nutrition/obesity [65]. There is evidence 
suggesting that placental FFA metabolism is influenced by maternal 
dietary deficiency, with a maternal vitamin-D deficiency reducing FFA 
levels in the placenta alongside a reduced placental weight [66]. Both 
FFA metabolism and transport would require examination to reveal 
details as to why LPD placentas demonstrated a higher FFA content in 
the current study. However, it is worth considering that as our paternal 
diet model cannot influence the availability of FFA in the mother, as 
these dams are maintained on identical standard chow diets, there is a 
possibility that the reduced placental FFA concentration is due to a 
potential programming of the placenta that is driven by the paternal 
diet. These changes, therefore, may be directed by differential gene 
expression in the placenta. 
Paternal diet can influence the epigenetic status of his sperm [19,67], 
and in turn sperm epigenetic modifications have been found to influence 
early embryo cell-lineage determination and placental gene expression 
[34,68,69]. In this study, we examined the expression of genes involved 
in maintenance and modification of epigenetic signatures, as well as key 
paternally-expressed imprinted genes. We found that paternal MD-LPD 
reduced placental expression of Dnmt3b. Dnmt3b, in partnership with 
Dnmt3a, is responsible for the establishment of genomic DNA methyl-
ation patterns in the early placenta following implantation [70–72]. Our 
results suggest that an excess of methyl-donor supplements in the 
paternal diet may be able to alter the epigenetic status of the placenta. 
However, alterations in DNA methyltransferase levels are not essential 
for changes to global methylation [73], supported by the lack of changes 
in global placental methylation in this study. This area requires further 
study to fully understand the role of paternal diet-mediated control of 
placental methylation and epigenetic status. 
In conclusion, this study revealed that paternal diet can direct fetal 
and placental weights, yet the influence of paternal LPD on fetal and 
placental development cannot be corrected by the simple addition of 
methyl-donor supplements. When taken together the findings for how 
paternal LPD impacts fetal and placental development suggests an 
uncoupling between placenta and fetus, in that the gross structure and 
gene expression profile mirrors that of NPD, yet LPD-associated fetal 
overgrowth was still observed. Furthermore, the supplementation of a 
poor diet with methyl-donors was not a ‘quick-fix’, as the placental 
morphology and gene expression was altered differentially to that seen 
in LPD placentas. These observations highlight the important need to 
understand how paternal sub-optimal diets influence the placenta and 
the impacts on fetal development, and further highlights that dietary 
supplementation in expecting fathers requires more in-depth studies to 
elucidate the underlying mechanisms that may alter placental devel-
opment and function and impact the programming of future 
generations. 
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